Data Source：
In February 2022, the National Cancer Center issued the "2016 China Cancer Incidence and Death Statistics".
Suitable for people
General population
- Mandatory annual physical exams for major disease screening
High-risk group
- Family history of malignant tumors and genetically susceptible populations
- People with chronic inflammation and sub-healthy people
- Persons with a clinical diagnosis of precancerous disease
- Occupation or area at risk
Technical Advantages
Early (precancerous, stage I), immediate
Display the current health risk of the detector, more suitable for cancer screening and prevention of the general health group, to realize the true management of cancer as a chronic disease
High sensitivity and specificity
Stage I non-small cell lung cancer: 85% sensitivity, 90% specificity. Recent results of more than 1,000 double-blind experiments with Changzheng Hospital showed a sensitivity of 100% and a specificity of 98%, in addition to the detection of 5 new cancer patients and 5 cases of precancerous lesions
Cost-effective, strong and early signal, easy and fast detection
Screens for multiple cancers at once, low cost, cost-effective
Early introduction of "multilevel, multiparameter" theory, thinking and methodology
One of the first teams in the world to propose "multi-cancer" screening (published in 2015), and the first to productize and commercialize the technology
No harm to the human body
Small volume of blood collection, 2ml-5ml, no radiation damage
One of the very few technologies to enable comprehensive management and tracking of cancer
Early Screening, Supportive Diagnosis, Efficacy Assessment, Prognostic Follow-up
Early (precancerous, stage I), immediate
Display the current health risk of the detector, more suitable for cancer screening and prevention of the general health group, to realize the true management of cancer as a chronic disease
High sensitivity and specificity
Stage I non-small cell lung cancer: 85% sensitivity, 90% specificity. Recent results of more than 1,000 double-blind experiments with Changzheng Hospital showed a sensitivity of 100% and a specificity of 98%, in addition to the detection of 5 new cancer patients and 5 cases of precancerous lesions
Cost-effective, strong and early signal, easy and fast detection
Screens for multiple cancers at once, low cost, cost-effective
Early introduction of "multilevel, multiparameter" theory, thinking and methodology
One of the first teams in the world to propose "multi-cancer" screening (published in 2015), and the first to productize and commercialize the technology
No harm to the human body
Small volume of blood collection, 2ml-5ml, no radiation damage
One of the very few technologies to enable comprehensive management and tracking of cancer
Early Screening, Supportive Diagnosis, Efficacy Assessment, Prognostic Follow-up
